Get startedLog in
    Picture of Seoul Pharma Co logo

    018680 — Seoul Pharma Co Cashflow Statement

    0.000.00%
    kr flag iconLast trade - 00:00
    HealthcareAdventurousMicro CapNeutral
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Seoul Pharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    2025
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSAnnual Audited AccountsAnnual Audited Accounts
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line-9,6898553,5171,699754
    Depreciation
    Amortisation
    Non-Cash Items5,6222,1592,3141,5841,516
    Unusual Items
    Other Non-Cash Items
    Changes in Working Capital-136-5,705-2,495-8,781-3,046
    Change in Accounts Receivable
    Change in Inventories
    Change in Prepaid Expenses
    Change in Other Assets
    Change in Accounts Payable
    Change in Accrued Expenses
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities-1,675-78.25,265-3,0081,886
    Capital Expenditures-1,168-1,299-1,894-2,230-894
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items68.2-33-3,9683,68750.8
    Sale/Maturity of Investment
    Change in Net Investments
    Purchase of Investments
    Other Investing Cash Flow
    Cash from Investing Activities-1,099-1,332-5,8621,457-843
    Financing Cash Flow Items0-8.940——
    Other Financing Cash Flow
    Total Cash Dividends Paid
    Net Issuance / Retirement of Debt
    Cash from Financing Activities1,535-483-4,4662,3801,328
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash-1,237-2,092-5,1559662,408